172 related articles for article (PubMed ID: 22747744)
1. [11C]phenytoin revisited: synthesis by [11C]CO carbonylation and first evaluation as a P-gp tracer in rats.
Verbeek J; Eriksson J; Syvänen S; Labots M; de Lange EC; Voskuyl RA; Mooijer MP; Rongen M; Lammertsma AA; Windhorst AD
EJNMMI Res; 2012 Jul; 2(1):36. PubMed ID: 22747744
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and preclinical evaluation of [11C]D617, a metabolite of (R)-[11C]verapamil.
Verbeek J; Syvänen S; Schuit RC; Eriksson J; de Lange EC; Windhorst AD; Luurtsema G; Lammertsma AA
Nucl Med Biol; 2012 May; 39(4):530-9. PubMed ID: 22226023
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic modeling of P-glycoprotein function at the rat and human blood-brain barriers studied with (R)-[11C]verapamil positron emission tomography.
Müllauer J; Kuntner C; Bauer M; Bankstahl JP; Müller M; Voskuyl RA; Langer O; Syvänen S
EJNMMI Res; 2012 Oct; 2(1):58. PubMed ID: 23072492
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of [11C]laniquidar as a tracer of P-glycoprotein: radiosynthesis and biodistribution in rats.
Luurtsema G; Schuit RC; Klok RP; Verbeek J; Leysen JE; Lammertsma AA; Windhorst AD
Nucl Med Biol; 2009 Aug; 36(6):643-9. PubMed ID: 19647170
[TBL] [Abstract][Full Text] [Related]
5. Tariquidar-induced P-glycoprotein inhibition at the rat blood-brain barrier studied with (R)-11C-verapamil and PET.
Bankstahl JP; Kuntner C; Abrahim A; Karch R; Stanek J; Wanek T; Wadsak W; Kletter K; Müller M; Löscher W; Langer O
J Nucl Med; 2008 Aug; 49(8):1328-35. PubMed ID: 18632828
[TBL] [Abstract][Full Text] [Related]
6. A pilot study to assess the efficacy of tariquidar to inhibit P-glycoprotein at the human blood-brain barrier with (R)-11C-verapamil and PET.
Wagner CC; Bauer M; Karch R; Feurstein T; Kopp S; Chiba P; Kletter K; Löscher W; Müller M; Zeitlinger M; Langer O
J Nucl Med; 2009 Dec; 50(12):1954-61. PubMed ID: 19910428
[TBL] [Abstract][Full Text] [Related]
7. Kinetic Models for Measuring P-glycoprotein Function at the Blood-Brain Barrier with Positron Emission Tomography.
Lubberink M
Curr Pharm Des; 2016; 22(38):5786-5792. PubMed ID: 27494063
[TBL] [Abstract][Full Text] [Related]
8. [11C]Flumazenil brain uptake is influenced by the blood-brain barrier efflux transporter P-glycoprotein.
Froklage FE; Syvänen S; Hendrikse NH; Huisman MC; Molthoff CF; Tagawa Y; Reijneveld JC; Heimans JJ; Lammertsma AA; Eriksson J; de Lange EC; Voskuyl RA
EJNMMI Res; 2012 Mar; 2():12. PubMed ID: 22455873
[TBL] [Abstract][Full Text] [Related]
9. (R)-[11C]verapamil PET studies to assess changes in P-glycoprotein expression and functionality in rat blood-brain barrier after exposure to kainate-induced status epilepticus.
Syvänen S; Luurtsema G; Molthoff CF; Windhorst AD; Huisman MC; Lammertsma AA; Voskuyl RA; de Lange EC
BMC Med Imaging; 2011 Jan; 11():1. PubMed ID: 21199574
[TBL] [Abstract][Full Text] [Related]
10. Increased permeability-glycoprotein inhibition at the human blood-brain barrier can be safely achieved by performing PET during peak plasma concentrations of tariquidar.
Kreisl WC; Bhatia R; Morse CL; Woock AE; Zoghbi SS; Shetty HU; Pike VW; Innis RB
J Nucl Med; 2015 Jan; 56(1):82-7. PubMed ID: 25500831
[TBL] [Abstract][Full Text] [Related]
11. Radiosynthesis and preclinical evaluation of [11C]prucalopride as a potential agonist PET ligand for the 5-HT4 receptor.
Buiter HJ; Windhorst AD; Huisman MC; De Maeyer JH; Schuurkes JA; Lammertsma AA; Leysen JE
EJNMMI Res; 2013 Apr; 3(1):24. PubMed ID: 23557209
[TBL] [Abstract][Full Text] [Related]
12. Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[(11)C]verapamil PET.
Kuntner C; Bankstahl JP; Bankstahl M; Stanek J; Wanek T; Stundner G; Karch R; Brauner R; Meier M; Ding X; Müller M; Löscher W; Langer O
Eur J Nucl Med Mol Imaging; 2010 May; 37(5):942-53. PubMed ID: 20016890
[TBL] [Abstract][Full Text] [Related]
13. Factors Governing P-Glycoprotein-Mediated Drug-Drug Interactions at the Blood-Brain Barrier Measured with Positron Emission Tomography.
Wanek T; Römermann K; Mairinger S; Stanek J; Sauberer M; Filip T; Traxl A; Kuntner C; Pahnke J; Bauer F; Erker T; Löscher W; Müller M; Langer O
Mol Pharm; 2015 Sep; 12(9):3214-25. PubMed ID: 26202880
[TBL] [Abstract][Full Text] [Related]
14. P-glycoprotein function at the blood-brain barrier in humans can be quantified with the substrate radiotracer 11C-N-desmethyl-loperamide.
Kreisl WC; Liow JS; Kimura N; Seneca N; Zoghbi SS; Morse CL; Herscovitch P; Pike VW; Innis RB
J Nucl Med; 2010 Apr; 51(4):559-66. PubMed ID: 20237038
[TBL] [Abstract][Full Text] [Related]
15. Developmental changes in P-glycoprotein function in the blood-brain barrier of nonhuman primates: PET study with R-11C-verapamil and 11C-oseltamivir.
Takashima T; Yokoyama C; Mizuma H; Yamanaka H; Wada Y; Onoe K; Nagata H; Tazawa S; Doi H; Takahashi K; Morita M; Kanai M; Shibasaki M; Kusuhara H; Sugiyama Y; Onoe H; Watanabe Y
J Nucl Med; 2011 Jun; 52(6):950-7. PubMed ID: 21571790
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic Modeling of (
García-Varela L; García DV; Kakiuchi T; Ohba H; Nishiyama S; Tago T; Elsinga PH; Tsukada H; Colabufo NA; Dierckx RAJO; van Waarde A; Toyohara J; Boellaard R; Luurtsema G
Mol Pharm; 2021 Jan; 18(1):416-428. PubMed ID: 33315404
[TBL] [Abstract][Full Text] [Related]
17. Interaction of 11C-tariquidar and 11C-elacridar with P-glycoprotein and breast cancer resistance protein at the human blood-brain barrier.
Bauer M; Karch R; Zeitlinger M; Stanek J; Philippe C; Wadsak W; Mitterhauser M; Jäger W; Haslacher H; Müller M; Langer O
J Nucl Med; 2013 Aug; 54(8):1181-7. PubMed ID: 23833270
[TBL] [Abstract][Full Text] [Related]
18. P-glycoprotein function at the blood-brain barrier imaged using 11C-N-desmethyl-loperamide in monkeys.
Liow JS; Kreisl W; Zoghbi SS; Lazarova N; Seneca N; Gladding RL; Taku A; Herscovitch P; Pike VW; Innis RB
J Nucl Med; 2009 Jan; 50(1):108-15. PubMed ID: 19091890
[TBL] [Abstract][Full Text] [Related]
19. Quantitative assessment of P-glycoprotein function in the rat blood-brain barrier by distribution volume of [11C]verapamil measured with PET.
Bart J; Willemsen AT; Groen HJ; van der Graaf WT; Wegman TD; Vaalburg W; de Vries EG; Hendrikse NH
Neuroimage; 2003 Nov; 20(3):1775-82. PubMed ID: 14642487
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the Blood-Brain Barrier Transport and Vulnerability to P-Glycoprotein-Mediated Drug-Drug Interaction of Domperidone versus Metoclopramide Assessed Using In Vitro Assay and PET Imaging.
Breuil L; Goutal S; Marie S; Del Vecchio A; Audisio D; Soyer A; Goislard M; Saba W; Tournier N; Caillé F
Pharmaceutics; 2022 Aug; 14(8):. PubMed ID: 36015284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
